2.19
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Entasis Therapeutics Holdings Inc | ETTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 2.19 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.19 | 2.19 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.40 - 3.8799 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.19 | USD |
Period:
Draw Mode:
Entasis Therapeutics Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 104.80M | 47.85M | 18.61M | $ - | $ - | -1.09 | -2.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 4.10% |
Entasis Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ETTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 1.83 | 2.20 | 1.78 | 2.18 | 375,205 | 0.36 | 19.67% |
| 6 Months | 1.77 | 2.20 | 1.62 | 2.08 | 170,452 | 0.42 | 23.73% |
| 1 Year | 2.63 | 3.8799 | 1.40 | 2.45 | 257,431 | -0.44 | -16.73% |
| 3 Years | 6.66 | 9.25 | 1.40 | 2.47 | 246,469 | -4.47 | -67.12% |
| 5 Years | 13.45 | 13.70 | 1.40 | 2.72 | 198,952 | -11.26 | -83.72% |
Entasis Therapeutics Description
| Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas). |